AVNS vs SIBN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with a -67% profit margin and negative ROE of -46.68%, undermining valuation appeal. While revenue growth is positive at 4.3% YoY and recent earnings surprises have been strong, the lack of sustained profitability, deteriorating insider sentiment, and poor long-term price performance (-72.6% over 5 years) raise serious concerns. The absence of Altman Z-Score and key financial data limits confidence, but current signals point to a distressed or speculative investment.
SIBN presents a classic high-risk, high-reward growth profile, characterized by a stable Piotroski F-Score of 4/9 and exceptional liquidity. While the company remains unprofitable with negative net margins, it demonstrates a strong trajectory of narrowing losses and consistent earnings beats (average surprise 40.87%). The balance sheet is fortress-like with a current ratio of 8.55 and low debt, but this is offset by heavy insider selling and a long-term bearish price trend. The disconnect between the 'Strong Buy' analyst consensus and the bearish insider sentiment suggests a speculative environment.
Compare Another Pair
Related Comparisons
AVNS vs SIBN: Head-to-Head Comparison
This page compares Avanos Medical, Inc. (AVNS) and SI-BONE, Inc. (SIBN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.